专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08961783B2 Apparatus and methods for preparative liquid chromatography 有权
标题翻译：制备液相色谱仪的设备和方法
公开(公告)号：US08961783B2
公开(公告)日：2015-02-24
申请号：US12555032
申请日：2009-09-08
申请人： Joshua A. Shreve , Michael R. Jackson
发明人： Joshua A. Shreve , Michael R. Jackson
IPC分类号： G01N30/34 , B01D15/16
CPC分类号： B01D15/18 , B01D15/166 , G01N30/34
摘要： A method of liquid chromatography includes providing one or more solvent reservoirs, providing a solvent pump, drawing one or more solvents into the pump in response to a pressure drop that promotes outgassing of the solvents, and dispersing outgassed bubbles into smaller bubbles to promote re-dissolution of the gas. A liquid-chromatography apparatus includes at least two solvent reservoirs, a pump, at least one bubble-dispersing unit that receives a pressurized flow of proportioned solvents from the pump, and a control unit. The control unit includes a processor and a memory that stores instructions; the control unit controls proportioning of solvents to obtain a preselected solvent composition, and pumping at flow rates to support preparative-scale or process-scale liquid chromatography.
摘要翻译：液相色谱法包括提供一个或多个溶剂储存器，提供溶剂泵，响应于促进溶剂除气的压降，将一种或多种溶剂吸入泵中，以及将脱气气泡分散成较小的气泡，溶解气体。液相色谱装置包括至少两个溶剂储存器，泵，至少一个气泡分散单元，其从泵接收加压的成比例溶剂流，以及控制单元。控制单元包括处理器和存储指令的存储器; 控制单元控制溶剂的比例以获得预选的溶剂组合物，并以流速泵送以支持制备规模或过程规模的液相色谱。

2. 发明授权

US08715350B2 Systems and methods for securing an implant in intervertebral space 有权
标题翻译：用于将植入物固定在椎间空间中的系统和方法
公开(公告)号：US08715350B2
公开(公告)日：2014-05-06
申请号：US12541658
申请日：2009-08-14
申请人： Brian P. Janowski , Jeffrey L. Trudeau , Michael R. Jackson , Russell M. Pietila
发明人： Brian P. Janowski , Jeffrey L. Trudeau , Michael R. Jackson , Russell M. Pietila
IPC分类号： A61F2/44
CPC分类号： A61F2/4425 , A61F2/30965 , A61F2/44 , A61F2/442 , A61F2/4611 , A61F2/4684 , A61F2002/3008 , A61F2002/30112 , A61F2002/30383 , A61F2002/30387 , A61F2002/30393 , A61F2002/30485 , A61F2002/30492 , A61F2002/305 , A61F2002/30565 , A61F2002/30571 , A61F2002/30578 , A61F2002/30579 , A61F2002/30594 , A61F2002/30601 , A61F2002/30662 , A61F2002/30677 , A61F2002/30823 , A61F2002/30841 , A61F2002/30846 , A61F2002/30884 , A61F2002/30894 , A61F2002/30899 , A61F2002/30904 , A61F2002/449 , A61F2002/4627 , A61F2002/4628 , A61F2220/0025 , A61F2230/0004 , A61F2250/0098 , A61F2310/00407 , A61F2310/00796
摘要： An intervertebral disc implant with upper and lower bearing members with an articulation interface between the members for providing relative motion therebetween. In one form, a securing member with an elongate shaft and a bone-engaging member on the shaft is disposed on one of the bearing members. The bone-engaging member is deployable into a bone-engaging position via rotational displacement of the shaft. In another form, a bone-engaging member is deployable via an actuator inserted into the implant body. In another form, the securing member secures an intervertebral implant in intervertebral space via deformation of the securing member causing a bone-engaging member of the securing member to be deployed into contact with an adjacent vertebra.
摘要翻译：一种椎间盘植入物，其具有上部和下部轴承部件，该部件具有在构件之间的铰接界面，用于在它们之间提供相对运动。在一种形式中，具有细长轴的固定构件和轴上的骨接合构件设置在轴承构件中的一个上。骨接合构件通过轴的旋转位移可展开成骨接合位置。在另一种形式中，骨接合构件可经由插入植入体内的致动器展开。在另一种形式中，固定构件通过固定构件的变形将椎间植入物固定在椎间空间中，使得固定构件的骨接合构件与相邻的椎骨相接触。

3. 发明申请

US20110065186A1 EX-VIVO PRIMING FOR GENERATING CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR NON-TUMOR ANTIGENS TO TREAT AUTOIMMUNE AND ALLERGIC DISEASE 有权
公开(公告)号：US20110065186A1
公开(公告)日：2011-03-17
申请号：US12899052
申请日：2010-10-06
申请人： Zeling Cai , Michael R. Jackson , Per A. Peterson , Wei-Xing Shi , Yan Kong , Juli DeGraw
发明人： Zeling Cai , Michael R. Jackson , Per A. Peterson , Wei-Xing Shi , Yan Kong , Juli DeGraw
IPC分类号： C12N5/10
CPC分类号： A61K39/0008 , A61K2035/122 , C12N5/0636 , C12N2501/23 , C12N2501/51 , C12N2501/58 , C12N2502/50 , C12N2502/99
摘要： Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo.

4. 发明申请

US20110027301A1 EX-VIVO PRIMING FOR GENERATING CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR NON-TUMOR ANTIGENS TO TREAT AUTOIMMUNE AND ALLERGIC DISEASE 有权
公开(公告)号：US20110027301A1
公开(公告)日：2011-02-03
申请号：US12887032
申请日：2010-09-21
申请人： Zeling Cai , Michael R. Jackson , Per A. Peterson , Wei-Xing Shi , Yan Kong , Juli DeGraw
发明人： Zeling Cai , Michael R. Jackson , Per A. Peterson , Wei-Xing Shi , Yan Kong , Juli DeGraw
IPC分类号： A61K39/00 , A61P37/08 , A61P11/06 , C12N5/02
CPC分类号： A61K39/0008 , A61K2035/122 , C12N5/0636 , C12N2501/23 , C12N2501/51 , C12N2501/58 , C12N2502/50 , C12N2502/99
摘要： Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo.

5. 发明申请

US20110021747A1 EX-VIVO PRIMING FOR GENERATING CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR NON-TUMOR ANTIGENS TO TREAT AUTOIMMUNE AND ALLERGIC DISEASE 有权
公开(公告)号：US20110021747A1
公开(公告)日：2011-01-27
申请号：US12892060
申请日：2010-09-28
申请人： Zeling Cai , Michael R. Jackson , Per A. Peterson , Wei-Xing Shi , Yan Kong , Juli DeGraw
发明人： Zeling Cai , Michael R. Jackson , Per A. Peterson , Wei-Xing Shi , Yan Kong , Juli DeGraw
IPC分类号： C07K7/06
CPC分类号： A61K39/0008 , A61K2035/122 , C12N5/0636 , C12N2501/23 , C12N2501/51 , C12N2501/58 , C12N2502/50 , C12N2502/99
摘要： Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo.

6. 发明申请

US20110020309A1 EX-VIVO PRIMING FOR GENERATING CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR NON-TUMOR ANTIGENS TO TREAT AUTOIMMUNE AND ALLERGICE DISEASE 有权
标题翻译：用于产生非肿瘤性抗原的CYTOTOXIC T淋巴细胞特异性治疗自发性和过敏性疾病的EX-VIVO预处理
公开(公告)号：US20110020309A1
公开(公告)日：2011-01-27
申请号：US12887052
申请日：2010-09-21
申请人： Zeling Cai , Michael R. Jackson , Per A. Peterson , Wei-Xing Shi , Yan Kong , Juli DeGraw
发明人： Zeling Cai , Michael R. Jackson , Per A. Peterson , Wei-Xing Shi , Yan Kong , Juli DeGraw
IPC分类号： A61K35/12 , C12N5/0783 , A61P37/02 , A61P3/10 , A61P29/00 , A61P17/06 , A61P25/00
CPC分类号： A61K39/0008 , A61K2035/122 , C12N5/0636 , C12N2501/23 , C12N2501/51 , C12N2501/58 , C12N2502/50 , C12N2502/99
摘要： Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo.
摘要翻译：可以通过用人造抗原呈递细胞呈递的IgE肽刺激静息幼稚CD8T细胞在体外产生来自IgE分子的抗原肽特异性的细胞毒性T淋巴细胞（CTL）。 IgE特异性CTL在体外裂解装载有IgE肽的靶细胞，并在体内抑制抗原特异性IgE反应。此外，将IgE特异性CTL过继转移至哮喘小鼠模型可以抑制肺部炎症和气道超敏反应的发展。 IgE特异性CTL提供过敏性哮喘和其他IgE介导的过敏性疾病的治疗。从非肿瘤自身抗原鉴定的抗原肽在体外诱导特异性细胞毒性T淋巴细胞（CTL）。由CD40L鉴定的肽诱导的CTL可以杀死活化的CD4T细胞。体外产生的CD40L特异性CTL可抑制体内所有同种型的CD4依赖性抗体反应。相比之下，来自IgE的抗原肽诱导的CTL特异性抑制IgE应答，CD40L特异性CTL过早转移到NOD小鼠早期延迟NOD小鼠的糖尿病发展。在活化的CD4T细胞上表达的非肿瘤自身抗原的体外产生的CTL调节体内的免疫应答。

7. 发明授权

US07842501B2 Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease 有权
标题翻译：用于产生特异于非肿瘤抗原的细胞毒性T淋巴细胞用于治疗自身免疫性和过敏性疾病的体外引发
公开(公告)号：US07842501B2
公开(公告)日：2010-11-30
申请号：US11935486
申请日：2007-11-06
申请人： Zeling Cai , Michael R. Jackson , Per A. Peterson , Wei-Xing Shi , Yan Kong , Juli DeGraw
发明人： Zeling Cai , Michael R. Jackson , Per A. Peterson , Wei-Xing Shi , Yan Kong , Juli DeGraw
IPC分类号： C12N5/08
CPC分类号： A61K39/0008 , A61K2035/122 , C12N5/0636 , C12N2501/23 , C12N2501/51 , C12N2501/58 , C12N2502/50 , C12N2502/99
摘要： Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo.
摘要翻译：可以通过用人造抗原呈递细胞呈递的IgE肽刺激静息幼稚CD8T细胞在体外产生来自IgE分子的抗原肽特异性的细胞毒性T淋巴细胞（CTL）。 IgE特异性CTL在体外裂解装载有IgE肽的靶细胞，并在体内抑制抗原特异性IgE反应。此外，将IgE特异性CTL过继转移至哮喘小鼠模型可以抑制肺部炎症和气道超敏反应的发展。 IgE特异性CTL提供过敏性哮喘和其他IgE介导的过敏性疾病的治疗。从非肿瘤自身抗原鉴定的抗原肽在体外诱导特异性细胞毒性T淋巴细胞（CTL）。由CD40L鉴定的肽诱导的CTL可以杀死活化的CD4T细胞。体外产生的CD40L特异性CTL可抑制体内所有同种型的CD4依赖性抗体反应。相比之下，来自IgE的抗原肽诱导的CTL特异性抑制IgE应答，CD40L特异性CTL过早转移到NOD小鼠早期延迟NOD小鼠的糖尿病发展。在活化的CD4T细胞上表达的非肿瘤自身抗原的体外产生的CTL调节体内的免疫应答。

8. 发明申请

US20100016974A1 SYSTEMS AND METHODS FOR SECURING AN IMPLANT IN INTERVERTEBRAL SPACE 有权
标题翻译：系统和方法来保护椎间隙内的植入物
公开(公告)号：US20100016974A1
公开(公告)日：2010-01-21
申请号：US12541658
申请日：2009-08-14
申请人： Brian P. JANOWSKI , Jeffrey L. TRUDEAU , Michael R. JACKSON , Russell M. PIETILA
发明人： Brian P. JANOWSKI , Jeffrey L. TRUDEAU , Michael R. JACKSON , Russell M. PIETILA
IPC分类号： A61F2/44
CPC分类号： A61F2/4425 , A61F2/30965 , A61F2/44 , A61F2/442 , A61F2/4611 , A61F2/4684 , A61F2002/3008 , A61F2002/30112 , A61F2002/30383 , A61F2002/30387 , A61F2002/30393 , A61F2002/30485 , A61F2002/30492 , A61F2002/305 , A61F2002/30565 , A61F2002/30571 , A61F2002/30578 , A61F2002/30579 , A61F2002/30594 , A61F2002/30601 , A61F2002/30662 , A61F2002/30677 , A61F2002/30823 , A61F2002/30841 , A61F2002/30846 , A61F2002/30884 , A61F2002/30894 , A61F2002/30899 , A61F2002/30904 , A61F2002/449 , A61F2002/4627 , A61F2002/4628 , A61F2220/0025 , A61F2230/0004 , A61F2250/0098 , A61F2310/00407 , A61F2310/00796
摘要： An intervertebral disc implant with upper and lower bearing members with an articulation interface between the members for providing relative motion therebetween. In one form, a securing member with an elongate shaft and a bone-engaging member on the shaft is disposed on one of the bearing members. The bone-engaging member is deployable into a bone-engaging position via rotational displacement of the shaft. In another form, a bone-engaging member is deployable via an actuator inserted into the implant body. In another form, the securing member secures an intervertebral implant in intervertebral space via deformation of the securing member causing a bone-engaging member of the securing member to be deployed into contact with an adjacent vertebra.
摘要翻译：一种椎间盘植入物，其具有上部和下部轴承部件，该部件具有在构件之间的铰接界面，用于在它们之间提供相对运动。在一种形式中，具有细长轴的固定构件和轴上的骨接合构件设置在轴承构件中的一个上。骨接合构件通过轴的旋转位移可展开成骨接合位置。在另一种形式中，骨接合构件可经由插入植入体内的致动器展开。在另一种形式中，固定构件通过固定构件的变形将椎间植入物固定在椎间空间中，使得固定构件的骨接合构件与相邻的椎骨相接触。

9. 发明授权

US07366591B2 System and method for vertical flight planning 有权
标题翻译：垂直飞行计划的系统和方法
公开(公告)号：US07366591B2
公开(公告)日：2008-04-29
申请号：US10871668
申请日：2004-06-21
申请人： Gary L. Hartmann , Michael R. Jackson , Brian E. O'Laughlin , Richard J. Snyder , Rosa N. Weber
发明人： Gary L. Hartmann , Michael R. Jackson , Brian E. O'Laughlin , Richard J. Snyder , Rosa N. Weber
IPC分类号： G05D1/00
CPC分类号： G05D1/0607 , G01C21/00
摘要： A method for performing performance prediction with respect to a vertical flight plan. A system performs performance prediction with respect to a vertical flight plan of an aircraft that includes determining which vertical flight plan rules of a plurality of vertical flight rules that have been loaded in a predictions processor are active by monitoring for criteria that are used to initiate or terminate one or more of the vertical flight plan rules. Aircraft state is predicted at waypoints along a lateral flight path in view of active vertical flight plan rules, and the predicted aircraft state is updated within an integrated flight plan database that stores prediction performance data associated with the aircraft's flight.
摘要翻译：一种用于对垂直飞行计划进行性能预测的方法。系统对飞行器的垂直飞行计划执行性能预测，其包括通过监视用于启动的标准来确定已经加载在预测处理器中的多个垂直飞行规则的哪些垂直飞行计划规则是活动的终止一个或多个垂直飞行计划规则。考虑到主动垂直飞行计划规则，沿着侧向飞行路径的航路点预测飞行器状态，并且在集成的飞行计划数据库内更新预测的飞行器状态，该飞行器状态存储与飞行器的飞行相关联的预测演奏数据。

10. 发明授权

US4635847A Field marker and method 失效
标题翻译：现场标记和方法
公开(公告)号：US4635847A
公开(公告)日：1987-01-13
申请号：US666174
申请日：1984-10-29
申请人： Michael R. Jackson
发明人： Michael R. Jackson
IPC分类号： A01B69/02 , B05B15/04 , B05B1/20
CPC分类号： A01B69/022 , B05B15/04
摘要： A field marker is disclosed for selectively dropping sections of rolled paper tissue to the ground surface to indicate the boundary of an area being treated with a liquid. The marker includes a device for mounting a tissue roll for rotation to facilitate unraveling the free end of the paper tissue. A gripping mechanism is provided to take hold of the free tissue end and pull it from the roll. The action is such that individual tissue sections are selectively removed from the tissue roll and dropped to the ground surface. Preferably, the area marked is slightly inward of the treatment pattern such that the dropped tissue sections are saturated by the liquid being applied and thereby secured to the ground surface.
摘要翻译：公开了一种现场标记，用于选择性地将卷纸组织的部分落到地面上，以指示用液体处理的区域的边界。标记器包括用于安装用于旋转的组织辊以便于解开纸组织的自由端的装置。提供夹持机构以保持自由组织端并将其从辊中拉出。该作用使得各个组织切片从组织辊中被选择性地去除并落到地面上。优选地，标记的区域处于处理图案的稍微内侧，使得落下的组织部分被施加的液体饱和，从而固定到地面。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式